Evidence map›Paper›PMID 41512838›Full record

ArticleAmerican journal of human genetics2026

Functional analysis of NPR2 variants supports the therapeutic rationale for CNP in short stature.

Raehoon Jeong, Sergio Covarrubias, Devanshi Shanghavi, Donald Ruhrmund, Karol Estrada, Dejie Zhou, Nofar Marom, Christopher R Bauer, Steven Froelich

Abstract read
In one paragraph

Article in American journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raehoon JeongResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Sergio CovarrubiasResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Devanshi ShanghaviResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Donald RuhrmundResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Karol EstradaResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Dejie ZhouResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Nofar MaromResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.
Christopher R BauerResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA. Electronic address: christopher.bauer@bmrn.com.
Steven FroelichResearch and Early Development, BioMarin Pharmaceutical Inc., San Rafael, CA 94901, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human height is a complex trait regulated by genetic and environmental factors. Several components of chondrocyte proliferation and differentiation regulatory pathways are implicated in short-stature disorders; one such component is natriuretic peptide receptor 2 (NPR2), the receptor for C-type natriuretic peptide. We developed a high-throughput GFP reporter assay to evaluate the functional impact of NPR2 missense variants on receptor activity, which was utilized alongside a commercially available CatchPoint assay, and previously published data. Measurements from these sources were integrated and annotated, providing an "activity score" for each variant, based on reduced or increased receptor activity. Unlike variant effect prediction tools that assign scores from benign to pathogenic, our method enabled us to distinguish loss-of-function and gain-of-function variants, categorizing 245 NPR2 missense variants, including 47 loss-of-function, 34 partial loss-of-function, and 14 gain-of-function variants, across the functional domains of NPR2. Activity scores showed a near-linear association with standing height (Pearson's correlation R

Indexed as

Body HeightDwarfismNatriuretic Peptide, C-TypeReceptors, Atrial Natriuretic FactorAtrial Natriuretic Factor Receptor BGain of Function MutationHumansMutation, MissenseAtrial Natriuretic Factor Receptor BNatriuretic Peptide, C-TypeReceptors, Atrial Natriuretic FactorachondroplasiaCNPC-type natriuretic peptidefunctional activity/assaygeneticheighthigh throughputmissense variantsnatriuretic peptide receptor BNPR2short staturevariant characterizationvariant of unknown significanceVUS

Identifiers

PMID41512838
PMCPMC12824620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.